Jerusalem, Israel.

NovellusDx, a Jerusalem based biotech company that is developing a functional assay for cancer diagnostics, today announced the appointment of Dr. Charles Woler, M.D., Ph.D., as the chairman of the company’s Board of Directors.

“We are delighted to appoint Dr. Woler as the Chairman of the Company’s Board of Directors. His well-known industry accomplishments, business acumen, and executive leadership will be of great value to our rapidly emerging organization,” said Mr. Haim Gil-Ad, Chief Executive Officer of NovellusDx.

“The first half of 2016 has already proved the immense value of Dr. Woler’s guidance. His stature in the field allowed him to leverage NovellusDx’s unique capabilities to close more deals with pharma, and initiate more clinical collaborations,” said Mr. Gil-Ad.

About Dr. Charles Woler, MD

Charles Woler has spent the last 30 years in the healthcare industry, both in large multinational pharmaceutical companies, SMEs and also in smaller, earlier stage Biotech companies.  His positions have included CEO of Roche France, CEO of SmithKline Beecham’s European pharmaceutical business (London), CEO of Cadus Pharmaceuticals (US), CEO of Neuro3d & Endotis Pharma (France), and recently Biomnis (France). He holds non-executive chairman and directorship positions in different European countries and the US.